The inhibition of Tyk2 selective inhibitors (BMS-986165) was addressed in early clinical and preclinical investigations [128], and a phase II study is ongoing to characterize the long-term safety and tolerability of Tyk2 selective inhibitors in SLE (NCT03920267). The gene discussed is TYK2; the disease is systemic lupus erythematosus.